| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 24, 2025 | Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights | Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALS
Clene planning to initiate the confirmatory Phase 3 RESTORE-ALS trial in subjects with ALS in mid-2025
Se... |
| Mar 12, 2025 | Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment | New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage
SALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopha... |
| Mar 6, 2025 | Clene to Present at the 37TH Annual Roth Conference | SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revoluti... |
| Mar 6, 2025 | Clene to Present at the 37TH Annual Roth Conference | SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revoluti... |
| Dec 10, 2024 | FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS | FDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY ALS Platform Trial to support earlier presented findings
FDA recommends a follow-up meeting to discu... |
| Nov 13, 2024 | Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights | Clene met with the U.S. Food and Drug Administration (FDA) on November 1, 2024, in a Type C meeting to discuss the potential for an accelerated approval pathway in ALS and are awaiting meeting minutes
Cash, cash equivalents and marketable s... |
| Oct 17, 2024 | Emergex Announces Company Name Change to “Gylden Pharma Limited” Reflecting Company’s Commitment to Advanced Core Technologies and Expanded Product Pipeline | ABINGDON, United Kingdom, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited, a clinical-stage biotechnology company that is addressing major global infectious diseases through the development of synthetic T cell-priming vac... |
| Oct 2, 2024 | Emergex T Cell-Priming Vaccine Candidate for Betacoronaviruses selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials | ABINGDON, United Kingdom, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company addressing major global infectious diseases through the development of synthe... |
| Sep 3, 2024 | Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference | SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mit... |
| Aug 7, 2024 | Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights | Survival analyses with CNM-Au8® 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baseline
CNM-Au8 treated participants in the HEALEY ALS Platform Trial with substantial neurofilament l... |
| Aug 5, 2024 | Clene to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase | SALT LAKE CITY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mito... |
| Jul 12, 2024 | Clene to Present at the Emerging Growth Conference | SALT LAKE CITY, July 12, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mito... |
| Jul 9, 2024 | Clene Announces 1-for-20 Reverse Stock Split | SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mito... |
| Jun 24, 2024 | Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference | SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mito... |
| Jun 18, 2024 | Emergex Announces MHRA Approval of MIA (IMP) Manufacturing and Import Authorisation License | ABINGDON, United Kingdom, June 18, 2024 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company addressing major global infectious diseases through the development of synthe... |
| Jun 18, 2024 | Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting | Survival analyses with CNM-Au8 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baseline (hazard ratio: 0.431, p=0.0002)
Average of 28% NfL reduction observed in an NfL responder subse... |
| May 29, 2024 | Spectral AI Set to Join Russell Microcap® Index | DALLAS, May 29, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound car... |
| May 15, 2024 | Spectral AI Announces Voting Results from 2024 Annual Meeting of Stockholders and the Appointment of Erich Spangenberg to the Board of Directors | DALLAS, May 15, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound car... |
| May 6, 2024 | Ratio Therapeutics Announces the Appointment of Marc Becker as Chief Financial Officer and Chief Operating Officer | BOSTON, May 6, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the... |
| May 2, 2024 | Spectral AI to Participate at the Sidoti Micro-Cap Virtual Investor Conference | DALLAS, May 02, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound car... |
| Jan 17, 2024 | SeptiCyte RAPID® By Immunexpress Receives Regulatory Clearance from Australian Therapeutic Goods Administration (TGA) | The Cost of Sepsis in Australia report (2021) estimated that there are >90,000 sepsis cases in Australia each year and estimated direct and indirect costs of $700 million and $4 billion respectively
SEATTLE and BRISBANE, Australia, Jan. ... |
| Jan 8, 2024 | Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension | Long-term CNM-Au8 treatment demonstrated improvement of vision as measured by low contrast visual acuity (LCLA), an assessment of visual function in people living with multiple sclerosis (MS), through 35 months from randomization, p |
| Nov 30, 2023 | Spectral AI to Participate in Benchmark’s 12th Annual Discovery One-on-One Conference | DALLAS, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in c... |
| Jun 26, 2023 | Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine | Peer-reviewed publication includes data from the CNM-Au8 Phase 2 RESCUE-ALS trial and its open-label-extension, up to 120 weeks of patient follow-up
/EIN News/ -- SALT LAKE CITY, June 26, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (... |
| Jun 24, 2023 | XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline for the Company’s Upcoming Annual and Special Meeting of Shareholders | /EIN News/ -- The proxy voting deadline for XORTX shareholders to vote their proxies is 10:00 a.m. (Calgary time) on Monday, June 26, 2023.
XORTX’s board of directors recommends shareholders vote FOR the election of all director nominees, F... |
| May 25, 2023 | Clene Awarded Grant From National Multiple Sclerosis Society to Advance Development of CNM-Au8® in Non-Active Progressive Multiple Sclerosis | /EIN News/ -- SALT LAKE CITY, May 25, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN), along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on r... |
| May 12, 2023 | Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights | ALS biomarker and long-term clinical data expected mid-year
Neurology expert Ben Greenberg, M.D., M.H.S., joined as Head of Medical
/EIN News/ -- SALT LAKE CITY, May 12, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its sub... |
| May 3, 2023 | Biotech nonprofit Nucleate to launch chapter in Miami to empower nextgen leaders | Facebook
Tweet
Pin
LinkedIn
Email
By Chloe Kirk and Natalie Ricciardi / Nucleate
How do you prepare scientists to be successful in biotechnology after graduate school?
It’s a question academia has struggled to answer for trainees who have p... |
| Feb 1, 2023 | XORTX Announces Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease | /EIN News/ -- CALGARY, Alberta, Feb. 01, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing ... |
| Dec 8, 2022 | XORTX Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Independent Study Shows Moderate Dose Strength of XORLO™ Attenuates Kidney Expansion
/EIN News/ -- CALGARY, Alberta, Dec. 08, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX |... |
| Nov 28, 2022 | XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study | XRX-OXY-101 Study will inform the dose choice in the upcoming Phase 3 Clinical Trial
/EIN News/ -- CALGARY, Alberta, Nov. 28, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX |... |
| Oct 4, 2022 | Biotricity Surpasses 2 billion Recorded and Analyzed Heartbeats for Atrial Fibrillation (AFib) | Data set of 2 billion heartbeats and growing allows Biotricity to scale faster and operate more efficiently with better automation, yielding growth and better margins in the future
REDWOOD CITY, CA / ACCESSWIRE / October 4, 2022 / Biotricit... |
| Oct 3, 2022 | Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial | The primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24 weeks
Prespecified exploratory analyses of the secondary survival endpoint for the 30 mg dose demonstrated a >90% reduction in risk of d... |
| Sep 30, 2022 | Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3 | SALT LAKE CITY, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing ... |
| Aug 15, 2022 | Biotricity Reports Financial Results for Fiscal 2023 First Quarter | REDWOOD CITY, CA / ACCESSWIRE / August 15, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced its financial results for ... |
| Aug 15, 2022 | Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights | Topline results from the Phase 2 VISIONARY-MS clinical trial with CNM-Au8® met the primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional Composite (mMSFC) compared to placebo over 48... |
| Aug 12, 2022 | Clene to Host VISIONARY-MS Results Call and Webcast on August 15 | SALT LAKE CITY, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing ... |
| Aug 9, 2022 | Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE® Revenues and Provides Corporate Update | Achieved Record Q2 2022 FIRDAPSE® Net Product Revenues of $53.0 Million, a 57.7% YoY Increase
Cash and Short-Term Investments at June 30, 2022 were $220.8 Million, with No Funded Debt
Completed Acquisition of Ruzurgi® U.S. and Mexico Commer... |
| Aug 5, 2022 | Biotricity to Host Fiscal First Quarter 2023 Financial Results Conference Call on August 15th at 4:30 p.m. ET | REDWOOD CITY, CA / ACCESSWIRE / August 5, 2022 /bbBiotricity Inc. (NYSE:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced it will host a conference ca... |
| Jul 19, 2022 | Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS | SALT LAKE CITY, July 19, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizin... |
| Jul 14, 2022 | Biotricity Reports Financial Results for Fiscal 2022 Fourth Quarter and Full Year | Company Reports Record Revenue and Improved Margins
REDWOOD CITY, CA / ACCESSWIRE / July 14, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology c... |
| Jul 14, 2022 | Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial | As of the July 5, 2022, data cutoff, early CNM-Au8® treatment resulted in a significant survival benefit (5 CNM-Au8 deaths vs. 14 placebo deaths, HR=0.301, p=0.0143)
CNM-Au8 treatment was well-tolerated, and there were no significant safety... |
| Jun 23, 2022 | Biotricity to Join Russell Microcap(R) Index | REDWOOD CITY, CA / ACCESSWIRE / June 23, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that the Company is expected... |
| May 23, 2022 | Biotricity to Present at the 2022 H.C. Wainwright Global Investment Conference on Tuesday May 24th | REDWOOD CITY, CA / ACCESSWIRE / May 23, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, is scheduled to present and will be participa... |
| May 9, 2022 | Clene Reports First Quarter 2022 Financial Results and Recent Operating Highlights | Cash, cash equivalents, restricted cash and marketable securities of $36.6 million as of March 31, 2022
Additional data from RESCUE-ALS presented at 2022 AAN Annual Meeting and MDA Clinical & Scientific Conference; Results show signific... |
| May 5, 2022 | Biotricity Issues Shareholder Update | Company highlights recent achievements and strategic initiatives setting the foundation to drive revenue growth to record levels in calendar 2022
National sales force growing, now covers 27 states for in-office clinic and physician demos
Wi... |
| Mar 22, 2022 | Biotricity to Launch Commercial Sales of Its Disruptive Cardiac Monitoring Device, Biotres in April 2022 | Company reports pre-order sales from existing customers of its wireless wearable device for early detection of cardiac arrhythmias
REDWOOD CITY, CA / ACCESSWIRE / March 22, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or th... |
| Mar 11, 2022 | Clene Reports Full Year 2021 Financial Results and Recent Operating Highlights | Cash and restricted cash of $50.3 million as of December 31, 2021
Visionary-MS Phase 2 Trial unblinded results expected 2H 2022
Healey ALS Platform Trial top-line data expected 2H 2022
COVID-19 Phase 2 Trial top-line results expected mid-ye... |
| Feb 15, 2022 | Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update | SAN DIEGO, Feb. 14, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, today reported financial results for its third quarter ended De... |
| Feb 8, 2022 | DarioHealth Announces Four New Employer Contracts | NEW YORK, Feb. 8, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced several new contracts to deliver its digital therapeutics solutions for four new employers. T... |
| Feb 8, 2022 | DarioHealth Announces Four New Employer Contracts | NEW YORK, Feb. 8, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced several new contracts to deliver its digital therapeutics solutions for four new employers. T... |
| Jan 25, 2022 | Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease | Berwyn, Pennsylvania--(Newsfile Corp. - January 25, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that ... |
| Jan 18, 2022 | DarioHealth to Host Investor Webinar on Navigating Emerging Digital Health Trends for Strategic Growth in 2022 | NEW YORK, Jan. 18, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) a leader in the global digital therapeutics (DTx) market, today announced that it will host an investor webinar on navigating the emerging digital health trends in 202... |
| Jan 18, 2022 | PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication | SALT LAKE CITY, Jan. 18, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced that the U.S. Food and Drug Administration (FDA) has approved it... |
| Jan 18, 2022 | DarioHealth to Host Investor Webinar on Navigating Emerging Digital Health Trends for Strategic Growth in 2022 | NEW YORK, Jan. 18, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) a leader in the global digital therapeutics (DTx) market, today announced that it will host an investor webinar on navigating the emerging digital health trends in 202... |
| Jan 13, 2022 | Aristea Therapeutics Announces Key Leadership Appointments to Advance Its Clinical Pipeline | SAN DIEGO, Jan. 13, 2022 /PRNewswire/ -- Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat rare serious inflammatory diseases, today announced the appointment of ... |
| Jan 10, 2022 | Annovis Bio Enhances Leadership Team with Two Senior Appointments | Company Appoints Eve Damiano, MS, RAC, as Senior Vice President of Regulatory Operations
Company Promotes Cheng Fang, Ph.D., to Senior Vice President of Research & Development
Berwyn, Pennsylvania--(Newsfile Corp. - January 10, 2022) - ... |
| Jan 6, 2022 | Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer | SOUTH SAN FRANCISCO, Calif., Jan. 5, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application... |
| Jan 6, 2022 | DarioHealth Announces Two New Contracts within the Employer Market | NEW YORK, Jan. 6, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced two new contracts today to provide its highly personalized digital therapeutics beginning in the fi... |
| Jan 6, 2022 | DarioHealth Announces Two New Contracts within the Employer Market | NEW YORK, Jan. 6, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced two new contracts today to provide its highly personalized digital therapeutics beginning in the fi... |
| Jan 5, 2022 | Avenge Bio Announces Closing of $45 Million Series A Financing | NATICK, Mass., Jan. 5, 2022 /PRNewswire/ -- Avenge Bio, Inc., a biotechnology company developing the LOCOcyte™ immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announce... |
| Jan 5, 2022 | Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401 | Berwyn, Pennsylvania--(Newsfile Corp. - January 5, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that t... |
| Jan 3, 2022 | Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences | Berwyn, Pennsylvania--(Newsfile Corp. - January 3, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that t... |
| Dec 27, 2021 | Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program STRO-002 for Treatment of Advanced Ovarian Cancer | SOUTH SAN FRANCISCO, Calif., Dec. 27, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro"), (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engin... |
| Dec 21, 2021 | DarioHealth Selected as Exclusive Digital Therapeutics Provider to a Leading Benefits Brokerage | NEW YORK, Dec. 21, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced a new strategic partnership with a leading employer benefits brokerage (the "Partner") t... |
| Dec 20, 2021 | Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders | Berwyn, Pennsylvania--(Newsfile Corp. - December 20, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today relea... |
| Dec 14, 2021 | Cartesian Therapeutics Adds Five Internationally Recognized Experts to Board of Advisors | GAITHERSBURG, Md., Dec. 14, 2021 /PRNewswire/ -- Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today announced the appointment of five internationall... |
| Dec 14, 2021 | Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics | Berwyn, Pennsylvania--(Newsfile Corp. - December 14, 2021) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (P... |
| Dec 2, 2021 | DarioHealth Announces Two New Contracts within the Employer and Provider Markets | NEW YORK, Dec. 2, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced new contracts today to provide its highly personalized digital therapeutics beginning in the first ... |
| Nov 22, 2021 | Sutro Biopharma to Participate in Two Upcoming Investor Conferences | SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational d... |
| Nov 18, 2021 | DarioHealth Announces Two New Employer Contracts | NEW YORK, Nov. 18, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has contracted with two employers to provide its highly personalized digital therape... |
| Nov 17, 2021 | Sutro Biopharma Announces Appointment of Heidi Hunter to Board of Directors | SOUTH SAN FRANCISCO, Nov. 17, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to... |
| Nov 15, 2021 | DarioHealth Appoints Seasoned Health Care Executive Jerrod Helms as Chief Commercial Officer | NEW YORK, Nov. 15, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the Company appointed Jerrod Helms to the newly created role of Chief Commercial Officer (CC... |
| Nov 11, 2021 | DarioHealth Announces Three New Contracts as Growth Continues to Accelerate Across the Employer and Provider Markets | NEW YORK, Nov. 11, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has contracted with two new employers and a new provider partner channel to provide ... |
| Nov 9, 2021 | Clene Reports Third Quarter 2021 Operating and Financial Highlights | Recently announced top-line results from RESCUE-ALS Phase 2 trial with CNM-Au8®, a gold nanocrystal suspension
VISIONARY-MS blinded interim data show clinically relevant improvements in the modified MS Functional Composite for the study pop... |
| Nov 3, 2021 | DarioHealth Partners with National Group Benefits Platform | NEW YORK, Nov. 3, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today a new strategic partnership with a leading national benefits administrative platform ("B... |
| Nov 3, 2021 | DarioHealth Partners with National Group Benefits Platform | NEW YORK, Nov. 3, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today a new strategic partnership with a leading national benefits administrative platform ("B... |
| Nov 2, 2021 | Clene Nanomedicine Announces Top-Line Results from Phase 2 RESCUE-ALS Clinical Trial | RESCUE-ALS Phase 2 Trial did not meet primary MUNIX biomarker endpoint or secondary FVC endpoint at week 36; MUNIX efficacy signal was observed at week 12 (p=0.057)
MUNIX trial results demonstrated protection of lower motor neurons in the p... |
| Oct 28, 2021 | PaxMedica Presents Clinical Data and New Analyses from a Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD) at the 2021 American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting | TARRYTOWN, N.Y., Oct. 28, 2021 /PRNewswire/ -- PaxMedica, Inc. ("PaxMedica" or the "Company"), a biopharmaceutical company developing medicines that help overcome the challenges of living with complex neurological condit... |
| Oct 27, 2021 | DarioHealth joins Virgin Pulse partner network | NEW YORK, Oct. 27, 2021 /PRNewswire/ -- DarioHealth today announced it has partnered with Virgin Pulse, the leading global provider of digital and live health and wellbeing solutions, making its next-gen digital therapeutic and health solut... |
| Oct 27, 2021 | DarioHealth joins Virgin Pulse partner network | NEW YORK, Oct. 27, 2021 /PRNewswire/ -- DarioHealth today announced it has partnered with Virgin Pulse, the leading global provider of digital and live health and wellbeing solutions, making its next-gen digital therapeutic and health solut... |
| Oct 25, 2021 | DarioHealth : Announces Contract with a U.S. National Employer to Provide Its Full Multi-Condition Suite Digital Therapeutic Solutions | NEW YORK, Oct. 25, 2021 /PRNewswire/ -- DarioHealth Corp. ("Dario," "DarioHealth" or the "Company") (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has entered ... |
| Oct 18, 2021 | DarioHealth : Unveils its Digital Musculoskeletal Solution Dario Move at HLTH 2021 | BOSTON, Oct. 18, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today the launch of Dario Move, a new digital physical therapy solution to manage common musculoskel... |
| Oct 18, 2021 | DarioHealth Unveils its Digital Musculoskeletal Solution Dario Move at HLTH 2021 | BOSTON, Oct. 18, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today the launch of Dario Move, a new digital physical therapy solution to manage common musculoskel... |
| Oct 12, 2021 | Aethlon Medical : Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier® | SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced the publication of a manuscript in the peer-revi... |
| Sep 30, 2021 | Sutro Biopharma : Announces Extension of Cytokine Derivative Research Program Under Collaboration with Merck | SOUTH SAN FRANCISCO, Calif., Sept. 30, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational ... |
| Sep 30, 2021 | PPD : Aethlon Medical Announces Contracting with PPD to Advance Hemopurifier Clinical Programs | SAN DIEGO, Sept. 30, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it has entered into an agreement with PPD,... |
| Sep 24, 2021 | DarioHealth to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference | NEW YORK, Sept. 24, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that management will participate in a fireside chat during the Cantor Fitzgerald Virtual Global ... |
| Sep 18, 2021 | Sutro Biopharma : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., Sept. 17, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational ... |
| Sep 16, 2021 | Sutro Biopharma : Announces Expansion of Leadership Team | SOUTH SAN FRANCISCO, Calif., Sept. 16, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational ... |
| Sep 10, 2021 | DiaCarta Receives CE/IVD for its New COVID 19 Screening Test that Identifies Delta Plus and New Variants | PLEASANTON, Calif., Sept. 10, 2021 /PRNewswire/ -- DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced that its new QuantiVirus™ SARS-CoV-2 Variant Detec... |
| Sep 9, 2021 | DarioHealth Chosen by Northeast Regional Employer | Dario Continues to Expand its Employer Contracts Across Broad Range of Solutions
NEW YORK, Sept. 9, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has... |
| Sep 9, 2021 | Obsidian Therapeutics : Announces Closing of $115 Million Series B Financing | CAMBRIDGE, Mass., Sept. 9, 2021 /PRNewswire/ -- Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a $115 million Series B financing with a premier syndicate of ... |
| Sep 7, 2021 | Aethlon Medical : to Present at the H.C. Wainwright 23rd Annual Global Investment Conference | SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that it will be presenting... |
| Aug 31, 2021 | DarioHealth Chosen by Regional Primary Care Provider PeopleOne Health as its Digital Behavioral Health Partner | NEW YORK, Aug. 31, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has been selected by regional primary care provider PeopleOne Health to be the digit... |
| Aug 19, 2021 | PaxMedica Selected by American Academy of Child and Adolescent Psychiatry (AACAP) to Present Data from its Recent Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD) in the Research Pipeline Program | TARRYTOWN, N.Y., Aug. 19, 2021 /PRNewswire/ -- PaxMedica, Inc. ("PaxMedica" or the "Company"), a biopharmaceutical company focused on developing medicines that help overcome the challenges of living with complex neurolog... |
| Aug 18, 2021 | Sutro Biopharma : Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer | SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational d... |
| Jul 30, 2021 | Blue Water Acquisition : Announces Date for Special Meeting of Stockholders to Vote on Transaction With Clarus Therapeutics, Inc. | GREENWICH, Conn., July 30, 2021 /PRNewswire/ -- Blue Water Acquisition Corp. (Nasdaq: BLUW) ("Blue Water"), a special purpose acquisition company ("SPAC") led by Joseph Hernandez, today announced that it has scheduled a ... |
| Jul 27, 2021 | DarioHealth : Launches Behavioral Health Solutions Globally in New Partnership with Workplace Options | NEW YORK, July 27, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, today announced the launch of its digital behavioral health solution that now includes Workplace Options (WPO) se... |
